REVOLV – EIC Transition innitiative
By shaping cell-laden volumes with light in mere seconds, REVOLV delivers reproducible, human-relevant 3D assays designed directly for pharmaceutical R&D workflows.
Method
A new standard for scalable 3D assay production.
Inspired by tomographic imaging, REVOLV uses volumetric bioprinting to shape a complete 3D structure inside a bioresin with targeted light. By forming the construct all at once, rather than layer by layer, the process reduces print time, mechanical stress and variability.
The ambition is not simply to print faster. The goal is multicellular, perfusable constructs at the speed, quality, and reproducibility industry demands.
<10s
print time per construct
≤30µm
feature resolution
Perfusable
vascular-like internal channels
Advanced bioresins
xeno-free bioresins
Innovation
Three advances. One integrated platform.
01
Xeno-free bioresins
Stable enough to print. Dynamic enough for biology. REVOLV replaces animal-derived matrices with bioresins that hold structure while remaining biologically permissive.
02
AI-guided precision
AI-guided calibration continuously optimizes print fidelity in real time, across diverse geometries and biomaterials.
03
Microplate-ready automation
The platform automates production of 5 mm-class, cell-laden constructs—ready for automated screening pipelines.
Impact
Designed for the next era of preclinical research
Preclinical research needs more reliable ways to understand how human tissues may respond to new drugs before clinical testing. Yet many models remain either too simple and do not fully capture human physiology, or are difficult to reproduce, and hard to scale.
REVOLV addresses this gap with complex, human-relevant 3D assay models that combine multicellular biology, organoid compatibility and perfusable architectures with the speed and consistency required by pharmaceutical R&D.
Our flagship proof point is a perfusable liver-relevant construct designed for drug screening and toxicity testing.
Consortium
Built by the pioneers of light-based tissue printing
REVOLV carries forward the breakthrough legacy of the EU-funded ENLIGHT project, translating cutting-edge scientific capability closer to industrial use.
Core Technology
The commercial pioneer of light-based tissue-printing systems, driving the platform's hardware and software toward industrial-grade performance.
Scientific Validation
Levato Lab (UMC Utrecht)
World-class pioneers in light-based tissue engineering, leading the scientific, biological, and organoid-based validation.
Impact & Engagement
INsociety
Specialized SME directing strategic communication, stakeholder engagement, and targeted impact creation.
For Strategic Enquiries
REVOLV welcomes technical and financial conversations with industrial, scientific, investment, and policy stakeholders interested in animal-free, high-throughput biofabrication.